Shares of Atul has soared 9% to Rs 1,485 on BSE the company announced that it has got the US Food and Drug Administration (FDA) approval for the Dapsone manufacture facility located at Valsad, Gujarat.
“This is to intimate that the Dapsone manufacture facility located at Atul, Valsad, Gujarat has now been approved by the US FDA,” Atul said in a statement.
The company has two business segments, namely, “Life Science Chemicals” and “Performance and Other Chemicals”. The life science chemical segment comprises several manufacturing facilities which include Dapsone manufacture facility, it added.
The stock opened at Rs 1,366 and touched a record high of Rs 1,514 on BSE after the announcements. The trading volumes on the counter more than doubled with a combined around 85,000 shares changed hands till 1345 hours on BSE and NSE.
“This is to intimate that the Dapsone manufacture facility located at Atul, Valsad, Gujarat has now been approved by the US FDA,” Atul said in a statement.
The company has two business segments, namely, “Life Science Chemicals” and “Performance and Other Chemicals”. The life science chemical segment comprises several manufacturing facilities which include Dapsone manufacture facility, it added.
The stock opened at Rs 1,366 and touched a record high of Rs 1,514 on BSE after the announcements. The trading volumes on the counter more than doubled with a combined around 85,000 shares changed hands till 1345 hours on BSE and NSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%